Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Research Area(s) / Expertise: Job title: Associate Professor
Prof Kaski is an Associate Professor at theCentre for Inherited Cardiovascular Diseases, UCL, London, UK. He is also a consultant paedriatric cardiologist, and Director of the Inherited Cardiovascular Diseases Unit at the Great Ormond Street Hospital for Children NHS Trust, UK. For his work on the genetic basis of pre-adolescent hypertrophic cardiomyopathy, Prof Kaski was awarded the Young… View more
Author(s): Byeong-Keuk Kim Added: 1 month ago
EuroPCR 25 - Subgroup analysis outcomes from OCCUPI show optical coherence tomography-guided percutaneous coronary intervention (PCI) is an effective intravascular imaging technique for complex lesions, having successfully met its composite primary outcome measure.We are joined by Dr Byeong-Keuk Kim (Yonsei University College of Medicine, Seoul, KR) to discuss subgroup analysis findings from the… View more
Author(s): Alexis Cutchins , Svetlana Blitshteyn , Rebecca Steinberg Added: 1 year ago
Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder that presents with positional tachycardia, amongst many other symptoms. Evidence for treatment options remains limited, and there are a multitude of associated conditions with overlapping symptoms which can make the diagnosis and management of POTS a difficult experience for providers and patients alike.This broadcast… View more
Author(s): Robert A Byrne Added: 1 year ago
ESC 2023 — Dr Robert Byrne (Mater Private Hospital, Dublin, IE) joins us on-site to discuss the new guidelines from the ESC covering the management of acute coronary syndromes. Acute Coronary Syndrome (ACS) is a broad spectrum of conditions, and the presentation can vary from a stable patient, to a patient who is critically ill. In the past, separate guidelines were issued for ST-Elevation… View more
Author(s): Masahiro Natsuaki Added: 1 year ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111). In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at… View more